JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - STOKE THERAPEUTICS INC
Financial Performance:
- No specific quarterly financial metrics (revenue, earnings, cash flow, debt, or deferred revenue) were disclosed in this transcript as the company is pre-commercial and in Phase III clinical development.
- The company referenced the Q3 earnings call held two weeks prior for financial updates, but those specific numbers were not included in this text.
Guidance and Future Outlook:
- Primary data readout for the pivotal Phase III study of Zirivenersen is expected in the third quarter of the next year (Week 26/28 endpoint).
- Management expressed high confidence in meeting the primary endpoint, noting the study is powered to detect a 46% treatment difference in seizure reduction with a p-value < 0.05, while historical data shows 80-85% reduction from baseline.
- Long-term goals include potential approval to address the root cause of Dravet syndrome, with the expectation of demonstrating sustained seizure reduction and cognitive/behavioral improvements over a lifetime.
Business Segments and Product Lines:
- Lead Asset (Zirivenersen): An antisense oligonucleotide targeting Dravet syndrome (genetic epilepsy) by upregulating the insufficient NAV1.1 protein. The Phase III study (n=162) is underway with zero dropouts; 130 of 162 patients have completed Week 24.
- Next Asset (ADOA): A medicine for Autosomal Dominant Optic Atrophy aimed at restoring vision rather than just stabilizing it, using a similar upregulation mechanism.
- Pipeline: Earlier-stage efforts focused on haploinsufficient diseases, primarily in the neurology/neuroscience space.
Market and Competitive Landscape:
- Target Population: Approximately 16,000 total Dravet patients in the US, with ~6,000 immediately addressable (diagnosed and likely under pediatric care); roughly 500-600 new diagnoses annually.
- Value Proposition: Unlike existing epilepsy drugs that only reduce seizures, Zirivenersen aims to improve neurodevelopmental cognition and behavior.
- Pricing Strategy: Management compares potential pricing to rare disease gene therapies such as Spinraza, Sarepta's exon skippers, and Duaveo (Rett syndrome), suggesting a multi-billion dollar blockbuster potential given the ~$1M/year cost of existing analogs.
- Unmet Need: Natural history studies indicate patients with Dravet syndrome typically "flatline" neurodevelopmentally around 18-24 months; current treatments fail to improve this trajectory.
Risks and Challenges:
- Regulatory Hurdles: The drug requires a successful Phase III primary endpoint to obtain approval; reliance on Phase I/II open-label extension (OLE) data alone was rejected by the FDA.
- Study Complexity: Historically, the FDA proposed hierarchical testing for cognitive endpoints, which could have led to failure if a single domain was missed (though this was recently adjusted).
- Disease Progression: Risk that untreated patients continue to decline or fail to improve without the mechanism of action provided by the drug.
Management Commentary and Tone:
- Tone: Confident and optimistic; CEO and Chief Patient Officer emphasized the unique position of having four years of safety/efficacy OLE data alongside an ongoing Phase III trial.
- Confidence: Management highlighted "zero dropouts" in the Phase III trial as a sign of excellent tolerability and increased statistical power.
- Strategic Shift: Noted a successful regulatory pivot to secure FDA agreement on the MC4 (composite) cognitive scoring method, which they argue better reflects the drug's holistic benefits.
Analyst Questions and Answers:
- Q: Pricing Power & Cognitive Benefits: Management clarified they have already demonstrated cognitive benefits (8-11 point gains on Vineland-3 over 68 weeks in OLE data) compared to the natural history (no improvement/decline). They argue payers value long-term OLE data for chronic treatments.
- Q: Market Size: Addressed the ~6,000 diagnosed patient pool and the growing identification of adult patients (30% of new diagnoses).
- Q: Phase III Endpoints & Powering: Explained the shift from hierarchical Vineland domains to a composite MC4 score (average of four domains) to reduce variability and enhance statistical power. The study is powered to show a 1.8-point MC4 improvement (p<0.05).
- Q: Safety Profile: Reiterated that zero dropouts in 162 patients and four years of OLE data (900-1000+ doses) indicate a highly tolerable safety profile, a rarity for gene therapies.
- Q: FDA Alignment: Explained the recent FDA agreement to use the MC4 score resulted from educating the agency on the disease's comorbidities and the drug's multi-domain effects, moving away from the previously proposed rigid hierarchy.
Other Key Points:
- Methodology Change: The transition to the MC4 scoring system allows for more robust statistical analysis by averaging four distinct domains (receptive communication, expressive communication, personal behavior, interpersonal skills), preventing "all-or-nothing" failures on single domains.
- Clinical Differentiation: Emphasized that untreated Dravet patients remain neurodevelopmentally static at a toddler level, whereas Zirivenersen-treated patients (even older children) demonstrate functional gains, such as using sentences and expressing pain.
- Study Progress: The Phase III trial is on track, with the primary endpoint (Week 28) approaching rapidly for the majority of the cohort.
- Company
- STOKE THERAPEUTICS INC
- Keywords
- STOKE THERAPEUTICS INC